Cargando…

Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases

Biomarker assisted preclinical/early detection and intervention in Alzheimer’s disease (AD) may be the key to therapeutic breakthroughs. One of the presymptomatic hallmarks of AD is the accumulation of beta-amyloid (Aβ) plaques in the human brain. However, current methods to detect Aβ pathology are...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jianfeng, Dong, Qunxi, Gui, Jie, Zhang, Jie, Su, Yi, Chen, Kewei, Thompson, Paul M., Caselli, Richard J., Reiman, Eric M., Ye, Jieping, Wang, Yalin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377280/
https://www.ncbi.nlm.nih.gov/pubmed/34421510
http://dx.doi.org/10.3389/fnins.2021.669595
_version_ 1783740626400968704
author Wu, Jianfeng
Dong, Qunxi
Gui, Jie
Zhang, Jie
Su, Yi
Chen, Kewei
Thompson, Paul M.
Caselli, Richard J.
Reiman, Eric M.
Ye, Jieping
Wang, Yalin
author_facet Wu, Jianfeng
Dong, Qunxi
Gui, Jie
Zhang, Jie
Su, Yi
Chen, Kewei
Thompson, Paul M.
Caselli, Richard J.
Reiman, Eric M.
Ye, Jieping
Wang, Yalin
author_sort Wu, Jianfeng
collection PubMed
description Biomarker assisted preclinical/early detection and intervention in Alzheimer’s disease (AD) may be the key to therapeutic breakthroughs. One of the presymptomatic hallmarks of AD is the accumulation of beta-amyloid (Aβ) plaques in the human brain. However, current methods to detect Aβ pathology are either invasive (lumbar puncture) or quite costly and not widely available (amyloid PET). Our prior studies show that magnetic resonance imaging (MRI)-based hippocampal multivariate morphometry statistics (MMS) are an effective neurodegenerative biomarker for preclinical AD. Here we attempt to use MRI-MMS to make inferences regarding brain Aβ burden at the individual subject level. As MMS data has a larger dimension than the sample size, we propose a sparse coding algorithm, Patch Analysis-based Surface Correntropy-induced Sparse-coding and Max-Pooling (PASCS-MP), to generate a low-dimensional representation of hippocampal morphometry for each individual subject. Then we apply these individual representations and a binary random forest classifier to predict brain Aβ positivity for each person. We test our method in two independent cohorts, 841 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and 260 subjects from the Open Access Series of Imaging Studies (OASIS). Experimental results suggest that our proposed PASCS-MP method and MMS can discriminate Aβ positivity in people with mild cognitive impairment (MCI) [Accuracy (ACC) = 0.89 (ADNI)] and in cognitively unimpaired (CU) individuals [ACC = 0.79 (ADNI) and ACC = 0.81 (OASIS)]. These results compare favorably relative to measures derived from traditional algorithms, including hippocampal volume and surface area, shape measures based on spherical harmonics (SPHARM) and our prior Patch Analysis-based Surface Sparse-coding and Max-Pooling (PASS-MP) methods.
format Online
Article
Text
id pubmed-8377280
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83772802021-08-21 Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases Wu, Jianfeng Dong, Qunxi Gui, Jie Zhang, Jie Su, Yi Chen, Kewei Thompson, Paul M. Caselli, Richard J. Reiman, Eric M. Ye, Jieping Wang, Yalin Front Neurosci Neuroscience Biomarker assisted preclinical/early detection and intervention in Alzheimer’s disease (AD) may be the key to therapeutic breakthroughs. One of the presymptomatic hallmarks of AD is the accumulation of beta-amyloid (Aβ) plaques in the human brain. However, current methods to detect Aβ pathology are either invasive (lumbar puncture) or quite costly and not widely available (amyloid PET). Our prior studies show that magnetic resonance imaging (MRI)-based hippocampal multivariate morphometry statistics (MMS) are an effective neurodegenerative biomarker for preclinical AD. Here we attempt to use MRI-MMS to make inferences regarding brain Aβ burden at the individual subject level. As MMS data has a larger dimension than the sample size, we propose a sparse coding algorithm, Patch Analysis-based Surface Correntropy-induced Sparse-coding and Max-Pooling (PASCS-MP), to generate a low-dimensional representation of hippocampal morphometry for each individual subject. Then we apply these individual representations and a binary random forest classifier to predict brain Aβ positivity for each person. We test our method in two independent cohorts, 841 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and 260 subjects from the Open Access Series of Imaging Studies (OASIS). Experimental results suggest that our proposed PASCS-MP method and MMS can discriminate Aβ positivity in people with mild cognitive impairment (MCI) [Accuracy (ACC) = 0.89 (ADNI)] and in cognitively unimpaired (CU) individuals [ACC = 0.79 (ADNI) and ACC = 0.81 (OASIS)]. These results compare favorably relative to measures derived from traditional algorithms, including hippocampal volume and surface area, shape measures based on spherical harmonics (SPHARM) and our prior Patch Analysis-based Surface Sparse-coding and Max-Pooling (PASS-MP) methods. Frontiers Media S.A. 2021-08-06 /pmc/articles/PMC8377280/ /pubmed/34421510 http://dx.doi.org/10.3389/fnins.2021.669595 Text en Copyright © 2021 Wu, Dong, Gui, Zhang, Su, Chen, Thompson, Caselli, Reiman, Ye and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Wu, Jianfeng
Dong, Qunxi
Gui, Jie
Zhang, Jie
Su, Yi
Chen, Kewei
Thompson, Paul M.
Caselli, Richard J.
Reiman, Eric M.
Ye, Jieping
Wang, Yalin
Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases
title Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases
title_full Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases
title_fullStr Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases
title_full_unstemmed Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases
title_short Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases
title_sort predicting brain amyloid using multivariate morphometry statistics, sparse coding, and correntropy: validation in 1,101 individuals from the adni and oasis databases
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377280/
https://www.ncbi.nlm.nih.gov/pubmed/34421510
http://dx.doi.org/10.3389/fnins.2021.669595
work_keys_str_mv AT wujianfeng predictingbrainamyloidusingmultivariatemorphometrystatisticssparsecodingandcorrentropyvalidationin1101individualsfromtheadniandoasisdatabases
AT dongqunxi predictingbrainamyloidusingmultivariatemorphometrystatisticssparsecodingandcorrentropyvalidationin1101individualsfromtheadniandoasisdatabases
AT guijie predictingbrainamyloidusingmultivariatemorphometrystatisticssparsecodingandcorrentropyvalidationin1101individualsfromtheadniandoasisdatabases
AT zhangjie predictingbrainamyloidusingmultivariatemorphometrystatisticssparsecodingandcorrentropyvalidationin1101individualsfromtheadniandoasisdatabases
AT suyi predictingbrainamyloidusingmultivariatemorphometrystatisticssparsecodingandcorrentropyvalidationin1101individualsfromtheadniandoasisdatabases
AT chenkewei predictingbrainamyloidusingmultivariatemorphometrystatisticssparsecodingandcorrentropyvalidationin1101individualsfromtheadniandoasisdatabases
AT thompsonpaulm predictingbrainamyloidusingmultivariatemorphometrystatisticssparsecodingandcorrentropyvalidationin1101individualsfromtheadniandoasisdatabases
AT casellirichardj predictingbrainamyloidusingmultivariatemorphometrystatisticssparsecodingandcorrentropyvalidationin1101individualsfromtheadniandoasisdatabases
AT reimanericm predictingbrainamyloidusingmultivariatemorphometrystatisticssparsecodingandcorrentropyvalidationin1101individualsfromtheadniandoasisdatabases
AT yejieping predictingbrainamyloidusingmultivariatemorphometrystatisticssparsecodingandcorrentropyvalidationin1101individualsfromtheadniandoasisdatabases
AT wangyalin predictingbrainamyloidusingmultivariatemorphometrystatisticssparsecodingandcorrentropyvalidationin1101individualsfromtheadniandoasisdatabases